The DESTINY-PanTumor02 trial is a pivotal phase II study evaluating the efficacy and safety of trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate targeting HER2, in patients with advanced HER2-expressing solid tumors, including endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and other cancers. The gene discussed is ERBB2; the disease is cancer.